Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis

References

• Kanis J A, Melton L J, 3rd, Christiansen C, Johnston C C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137–1141
   PubMed Web of Science ®Google Scholar
• Nachtigall L E, Nachtigall R H, Nachtigall R D, Beckman E M. Estrogen replacement therapy I: a 10-year prospective study in relationship to osteoporosis. Obstet Gynecol 1979; 53: 277–281
   PubMed Web of Science ®Google Scholar
• Tepper R, Goldberger S, Cohen I, Segal J, Yarkoni S, Fejgin M, Beyth Y. Estrogen replacement in post-menopausal women: are we currently overdosing our patients?. Gynecol Obstet Invest 1994; 38: 113–116
   Google Scholar
• Utian W H, Shoupe D, Bachmann G, Pinkerton J V, Pickar J H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 75: 1065–1079
   PubMed Web of Science ®Google Scholar
• Pickar J H, Yeh I, Wheeler J E, Cunnane M F, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001; 76: 25–31
   PubMed Web of Science ®Google Scholar
• Lobo R A, Bush T, Carr B R, Pickar J H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13–24
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Monteleone P, Genazzani A R. Low-dose hormone replacement therapy: effects on bone. Climacteric 2002; 5: 135–139
   PubMed Web of Science ®Google Scholar
• Mizunuma H, Okano H, Soda M, Kagami I, Miyamoto S, Tokizawa T, Honjo S, Ibuki Y. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. Maturitas 1997; 27: 69–76
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani A R. Postmenopausal femur bone loss: effects of a low dose hormone replacement therapy. Maturitas 2003; 45: 175–183
   PubMed Web of Science ®Google Scholar
• van de Weijer P H, Mattsson L A, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy. Maturitas 2007; 56: 231–248
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, LaCroix A Z, Kooperberg C, Stefanick M L, Jackson R D, Beresford S A, Howard B V, Johnson K C, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419–427
   PubMed Web of Science ®Google Scholar
• Cummings S R, Eckert S, Krueger K A, Grady D, Powles T J, Cauley J A, Norton L, Nickelsen T, Bjarnason N H, Morrow M, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 1999; 281: 2189–2197
   PubMed Web of Science ®Google Scholar
• Cauley J A, Norton L, Lippman M E, Eckert S, Krueger K A, Purdie D W, Farrerons J, Karasik A, Mellstrom D, Ng K W, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Res Treat 2001; 65: 125–134
   PubMed Web of Science ®Google Scholar
• Meunier P J, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper M W. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Osteoporos Int 1999; 10: 330–336
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black D M, Mitlak B H, Knickerbocker R K, Nickelsen T, Genant H K, Christiansen C, Delmas P D, Zanchetta J R, Stakkestad J, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999; 282: 637–645
   PubMed Web of Science ®Google Scholar
• Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. J Am Med Assoc 2001; 285: 1415–1418
   PubMedGoogle Scholar
• Delmas P D, Confavreux E, Garnero P, Fardellone P, de Vernejoul M C, Cormier C, Arce J C. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000; 11: 177–187
   PubMed Web of Science ®Google Scholar
• Greenwald M W, Gluck O S, Lang E, Rakov V. Oral hormone therapy with 17β-estradiol and 17β-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. Menopause 2005; 12: 741–748
   PubMed Web of Science ®Google Scholar
• Delmas P D, Bjarnason N H, Mitlak B H, Ravoux A C, Shah A S, Huster W J, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–1647
   PubMed Web of Science ®Google Scholar
• Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamara T, Itabashi A, Sarkar S, Harper K. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporosis Int 2003; 14: 793–800
   PubMed Web of Science ®Google Scholar
• Johnston C C, Jr, Bjarnason N H, Cohen F J, Shah A, Lindsay R, Mitlak B H, Huster W, Draper W, Harper K D, Heath H, 3rd, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000; 160: 3444–3450
   PubMed Web of Science ®Google Scholar
• Michalska D, Stepan J J, Basson B R, Pavo I. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006; 91: 870–877
   PubMed Web of Science ®Google Scholar
• Prestwood K M, Gunness M, Muchmore D B, Lu Y, Wong M, Raisz L G. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 2197–2202
   PubMed Web of Science ®Google Scholar
• Draper M W, Flowers D E, Huster W J, Neild J A, Harper K D, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835–842
   PubMed Web of Science ®Google Scholar
• Ravn P, Bidstrup M, Wasnich R D, Davis J W, McClung M R, Balske A, Coupland C, Sahota O, Kaur A, Daley M, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131: 935–942
   PubMed Web of Science ®Google Scholar
• Marcus R, Holloway L, Wells B, Greendale G, James M K, Wasilauskas C, Kelaghan J. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res 1999; 14: 1583–1595
   PubMedGoogle Scholar
• Tsai K S, Yen M L, Pan H A, Wu M H, Cheng W C, Hsu S H, Yen B L, Huang K E. Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women. Osteoporos Int 2001; 12: 1020–1025
   PubMed Web of Science ®Google Scholar
• Reid I R, Eastell R, Fogelman I, Adachi J D, Rosen A, Netelenbos C, Watts N B, Seeman E, Ciaccia A V, Draper M W. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. Arch Intern Med 2004; 164: 871–879
   PubMed Web of Science ®Google Scholar
• Peeyananjarassri K, Baber R. Effects of low-dose hormone therapy on menopausal symptoms, bone mineral density, endometrium, and the cardiovascular system: a review of randomized clinical trials. Climacteric 2005; 8: 13–23
   PubMed Web of Science ®Google Scholar
• Weinstein R S, Parfitt A M, Marcus R, Greenwald M, Crans G, Muchmore D B. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporosis Int 2003; 14: 814–822
   PubMed Web of Science ®Google Scholar